cell therapy
Immatics Prices $150M Stock Offering
The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.
In Brief This Week: ADLM, Verismo, Gemma, Denovo, Flatiron Health, Foresight, Naveris
News items for the week of Oct. 7, 2024.
The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US and German health authorities.
Immatics to Raise $150M in Public Stock Offering
The firm is developing T-cell receptor therapies for advanced solid tumors including metastatic melanoma.
Aurigene Oncology Advancing BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma Trial
After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.